<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82361">
  <stage>Registered</stage>
  <submitdate>19/02/2008</submitdate>
  <approvaldate>21/02/2008</approvaldate>
  <actrnumber>ACTRN12608000099325</actrnumber>
  <trial_identification>
    <studytitle>Fish oil and hip fracture</studytitle>
    <scientifictitle>Effect of n-3 fatty acids on outcomes following hip fracture: a pilot study to investigate proof of concept, feasibility of recruitment and adherence to a 6 week fish oil intervention.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Elderly hip fracture patients with malnutrition</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Fractures</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>6 week fish oil intervention (15ml/day liquid fish oil (4.9g EPA) OR 
9 fish oil capsules/day (4.8g EPA)</interventions>
    <comparator>No fish oil</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percent weight change</outcome>
      <timepoint>At 6 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Levels of inflammatory markers as follows, measured by blood test:
1 C-reactive protein (CRP) 
2 Tumour necrosis factor alpha (TNF-alpha)
3 Interleukin 1 beta (IL-1beta)
4 Interleukin 6 (IL-6)</outcome>
      <timepoint>At 6 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Levels of eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) in erythrocyte membrane, measured by blood test</outcome>
      <timepoint>At 6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body composition, assessed by bioelectrical impedance analysis (BIA)</outcome>
      <timepoint>At 6 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>60 years or over
Hip fracture sufferers
No cognitive impairment according to the Mini Mental State Examination (MMSE score over 24/30)
At risk of subsequent weight loss according to the Simplified Nutrition Appetite Questionnaire (SNAQ score less than or =14/20) 
Elevated CRP (6mg/L or more)
Able to consent</inclusivecriteria>
    <inclusiveminage>60</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Allergy to fish
Initiation of anti-inflammatory corticosteroids within the prior two weeks
Ingestion of n-3 fatty acid supplements within four weeks of study initiation
Life expectancy less than 6 weeks</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed numbered envelopes</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>3/03/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>5041</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Dr Michelle Miller</primarysponsorname>
    <primarysponsoraddress>Department of Nutrition &amp; Dietetics
Flinders University
GPO Box 2100
Adelaide SA 5001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Flinders University</fundingname>
      <fundingaddress>G4, Flinders Medical Centre Flats,
Flinders Drive
Bedford Park SA 5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Professor Maria Crotty</sponsorname>
      <sponsoraddress>Department of Rehabilitation and Aged Care
Flinders University
GPO Box 2100
Adelaide SA 5001</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Inflammatory markers have been found to be raised in hip fracture patients.  It is plausible that fish oils will counteract production of these chemicals and reduce weight and muscle loss which is experienced in many of these patients.  This study will investigate proof of this concept, feasibility of recruitment and adherence to fish oil liquid or capsules.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Repatriation General Hospital Research and Ethics Committee</ethicname>
      <ethicaddress>Repatriation General Hospital
Daws Road
Daw Park
South Australia 5041</ethicaddress>
      <ethicapprovaldate>6/02/2008</ethicapprovaldate>
      <hrec>72/07</hrec>
      <ethicsubmitdate>24/10/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Michelle Miller</name>
      <address>Dept Nutrition &amp; Dietetics
Flinders University
GPO Box 2100
Adelaide SA 5001</address>
      <phone>08 8204 5328</phone>
      <fax>08 8204 6406</fax>
      <email>Michelle.Miller@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Michelle Miller</name>
      <address>Dept Nutrition &amp; Dietetics
Flinders University
GPO Box 2100
Adelaide SA 5001</address>
      <phone>08 8204 5328</phone>
      <fax>08 8204 6406</fax>
      <email>Michelle.Miller@flinders.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Michelle Miller</name>
      <address>Dept Nutrition &amp; Dietetics
Flinders University
GPO Box 2100
Adelaide SA 5001</address>
      <phone>08 8204 5328</phone>
      <fax>08 8204 6406</fax>
      <email>Michelle.Miller@flinders.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>